In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis

BACKGROUND: Sustained drug delivery is a large unmet clinical need in glaucoma. Here, we incorporated a Myocardin-Related Transcription Factor/Serum Response Factor inhibitor, CCG-222740, into slow release large unilamellar vesicles derived from the liposomes DOTMA (1,2-di-O-octadecenyl-3-trimethyla...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Nanobiotechnology
Auteurs principaux: Tagalakis, Aristides D., Madaan, Shivam, Larsen, Scott D., Neubig, Richard R., Khaw, Peng T., Rodrigues, Ian, Goyal, Saurabh, Lim, Kin Sheng, Yu-Wai-Man, Cynthia
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6258153/
https://ncbi.nlm.nih.gov/pubmed/30482196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12951-018-0425-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires